Cardiff Oncology (CRDF) CSO granted 300,000 stock options expiring 2036
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Cardiff Oncology’s Chief Scientific Officer, Tod Smeal, received a grant of stock options covering 300,000 shares of common stock at an exercise price of $1.63 per share. These options were awarded as compensation, not purchased in the open market, and expire on April 14, 2036.
Following this grant, Smeal holds stock options for 1,279,805 shares in total. The award vests over time: 75,000 options vest on April 14, 2027, and 6,250 options vest monthly for 36 months thereafter, creating a multi‑year retention and incentive structure.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Smeal Tod
Role
Chief Scientific Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Options | 300,000 | $0.00 | -- |
Holdings After Transaction:
Stock Options — 1,279,805 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 300,000 options
Exercise price: $1.63 per share
Total options after grant: 1,279,805 options
+3 more
6 metrics
Options granted
300,000 options
Grant to Chief Scientific Officer on April 14, 2026
Exercise price
$1.63 per share
Strike price for newly granted options
Total options after grant
1,279,805 options
Derivative holdings following the reported transaction
Expiration date
April 14, 2036
Final exercise date for the granted options
Initial vesting tranche
75,000 options
Vests on April 14, 2027
Monthly vesting amount
6,250 options
Vest monthly for 36 months after April 14, 2027
Key Terms
stock options, exercise price, derivative securities, vesting, +1 more
5 terms
stock options financial
"Chief Scientific Officer, Tod Smeal, received a grant of stock options covering 300,000 shares"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise price financial
"stock options covering 300,000 shares of common stock at an exercise price of $1.63 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
derivative securities financial
"After the grant, Tod Smeal holds stock options representing 1,279,805 underlying shares of common stock as derivative securities"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
vesting financial
"The award vests over time: 75,000 options vest on April 14, 2027, and 6,250 options vest monthly"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
Form 4 regulatory
"After the grant, Tod Smeal holds stock options representing 1,279,805 underlying shares reported on Form 4"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
FAQ
What insider transaction did Cardiff Oncology (CRDF) report for Tod Smeal?
Cardiff Oncology reported that Chief Scientific Officer Tod Smeal received a grant of 300,000 stock options. The options relate to common stock and were issued as compensation under a vesting schedule, rather than being bought or sold in the open market.
What is the exercise price and expiration date of Tod Smeal’s new CRDF stock options?
Tod Smeal’s newly granted Cardiff Oncology stock options have an exercise price of $1.63 per share. The options expire on April 14, 2036, giving a long-dated window in which they may be exercised if vesting conditions are satisfied.
How do Tod Smeal’s Cardiff Oncology stock options vest over time?
The grant includes time-based vesting: 75,000 options vest on April 14, 2027. An additional 6,250 options then vest monthly for 36 months, creating a staggered schedule that extends vesting over several years to support ongoing retention.
How many Cardiff Oncology derivative securities does Tod Smeal hold after this Form 4?
After the grant, Tod Smeal holds stock options representing 1,279,805 underlying shares of Cardiff Oncology common stock. This figure reflects his total derivative holdings reported in the filing following the award of the 300,000 new options.